Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07288008 · ClinicalTrials.gov registry record · NA

Transcranial Alternating Current Stimulation (tACS) for the Treatment of Anxiety in Veterans: An Open-Label Pilot Study

A NA study of Anxiety, sponsored by Birmingham VA Health Care System.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT07288008: Recruiting NA study of Anxiety, sponsored by Birmingham VA Health Care System.

NCT07288008 is a NA study of Anxiety that is actively recruiting participants, run by Birmingham VA Health Care System. The registered enrollment target is 40 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07288008, a NA study of Anxiety, is actively recruiting participants, sponsored by Birmingham VA Health Care System.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

Transcranial alternating current stimulation (tACS) in a wearable brain stimulation device that delivers a low intensity, pulsed, alternating current via scalp electrodes. Prior sham-controlled clinical trials have shown the therapeutic effects and safety of tACS for the treatment of anxiety and depression. In addition, tACS is rapid acting and well tolerated. After the device is issued to the patient during an in-office orientation and training session, the tACS device can be safely used by the patient at the convenience of their own home. Up to 40 Veterans under that age of 70 who have clinically significant anxiety will be enrolled in an 8-week open-label trial of Model FW-200 tACS to evaluate feasibility, acceptability, adherence and impact on anxiety, depression, post-traumatic stress disorder (PTSD), sleep and neurocognitive measures. Participants may have a concurrent diagnosis of major depressive disorder (MDD) and/or PTSD.

Primary Outcome

Generalized Anxiety Disorder-7 (GAD-7) is a 7-item self-report rated on a 4-point Likert scale of frequency ranging from 0=not at all to 3=nearly every day. Total score ranges from 0 to 21. A total score is interpreted as follows: ≤4 minimal anxiety, 5-9 mild anxiety, 10-14 moderate anxiety, and 15-21 severe anxiety. The GAD-7 is sensitive to detecting a change in anxiety severity over the course of treatment.

Conditions Studied

Interventions

  • DEVICE Transcranial alternating current stimulator

Study Locations (1)

Alabama

  • Birmingham VA - Birmingham

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-12-15
Est. Completion 2028-06-30
Phase NA
Birmingham VA Health Care System

1 total trials

What NCT07288008 shows while recruiting

NCT07288008 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (91% lower).

The record links to 1 condition, with Anxiety appearing as the primary indexed condition, and to 1 intervention - of which Transcranial alternating current stimulator is the first listed.

NCT07288008 reports a single indexed study location in Alabama.

Frequently Asked Questions

What is clinical trial NCT07288008 about?

NCT07288008 is a clinical study titled "Transcranial Alternating Current Stimulation (tACS) for the Treatment of Anxiety in Veterans: An Open-Label Pilot Study". Transcranial alternating current stimulation (tACS) in a wearable brain stimulation device that delivers a low intensity, pulsed, alternating current via scalp electrodes. Prior sham-controlled clinical trials have shown the therapeutic effects and safety of tACS for the treatment of anxiety and dep...

What is the current status of trial NCT07288008?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2025-12-15. Estimated completion is 2028-06-30.

What conditions does trial NCT07288008 study?

This clinical trial studies the following conditions: Anxiety.

What interventions are being tested in trial NCT07288008?

The interventions under investigation include: Transcranial alternating current stimulator (DEVICE).

Who is sponsoring clinical trial NCT07288008?

This trial is sponsored by Birmingham VA Health Care System, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07288008 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Anxiety

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07288008's enrollment target sits among peer trials

40 266th of 364 higher than 83 of 364 other Anxiety trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Anxiety trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07288008, the US trial registry maintained by the National Library of Medicine. NCT07288008 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.